Table 3. Site of recurrence according to mutational status.
Bone | Liver | Brain | Pleuro-pericardial | Lung | Adrenal glands | |
---|---|---|---|---|---|---|
Wild type (n=258) | 57 (22%) | 39 (15%) | 26 (10%) | 37 (14%) | 89 (35%) | 10 (4%) |
EGFR (n=27) | 0 | 8 (30%) | 16 (59%) | 2 (7%) | 1 (4%) | 0 |
KRAS G12C (n=91) | 54 (59%) | 1 (1%) | 7 (8%) | 9 (10%) | 16 (18%) | 4 (4%) |
KRAS G12V (n=85) | 0 | 4 (5%) | 0 | 80 (94%) | 1 (1%) | 0 |
Other KRAS (n=20) | 7 (35%) | 4 (20%) | 2 (10%) | 0 (0%) | 5 (25%) | 2 (10%) |
P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.13 |
Abbreviations: EGFR=epidermal growth factor receptor; KRAS=V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue.
Data are given as n (%).